Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 04, 2022, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg".